Funds and ETFs AbbVie Inc.

ABBV

US00287Y1091

Name	Weight	AuM	1st Jan change	Investor Rating
CABANA TARGET LEADING SECTOR MODERATE ETF - USD	0.35%	0 M€	-1.48%	-
FRANKLIN U.S. LOW VOLATILITY HIGH DIVIDEND INDEX ETF - USD	0.33%	0 M€	-0.22%
FIDELITY U.S. HIGH QUALITY CURRENCY NEUTRAL INDEX ETF - CAD	0.33%	0 M€	+6.12%	-
LEADERSHARES EQUITY SKEW ETF - USD	0.32%	0 M€	+3.22%	-
FIDELITY U.S. HIGH DIVIDEND CURRENCY NEUTRAL INDEX ETF - CAD	0.31%	0 M€	+6.07%	-
FIDELITY U.S. MOMENTUM CURRENCY NEUTRAL INDEX ETF - CAD	0.30%	0 M€	-.--%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0.28%	0 M€	+5.23%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.28%	0 M€	+5.36%	-
RH TACTICAL ROTATION ETF - USD	0.24%	0 M€	+11.38%	-
ADAPTIVE RH HEDGED MULTI-ASSET INCOME ETF - USD	0.23%	0 M€	+3.15%	-
SYNTAX STRATIFIED TOTAL MARKET II ETF - USD	0.21%	0 M€	+4.60%	-
SYNTAX STRATIFIED U.S. TOTAL MARKET HEDGED ETF - USD	0.21%	0 M€	+0.78%	-
SYNTAX STRATIFIED U.S. TOTAL MARKET ETF - USD	0.21%	0 M€	+4.60%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0.20%	0 M€	+3.03%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	0.19%	0 M€	+2.65%	-
IQ REAL RETURN ETF - USD	0.16%	6 M€	+3.89%
INFRACAP EQUITY INCOME FUND ETF - USD	0.15%	0 M€	-1.76%	-
MERLYN.AI BULL-RIDER BEAR-FIGHTER ETF - USD	0.13%	15 M€	-1.62%	-

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

2024-05-15 - BofA Securities Health Care Conference

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

160.4 USD

Average target price

181.6 USD

Spread / Average Target

+13.15%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+3.54%	283B
ELI LILLY AND COMPANY	+32.95%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.97%	358B
MERCK & CO., INC.	+18.83%	328B
ASTRAZENECA PLC	+15.70%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+6.70%	165B
PFIZER, INC.	-1.81%	160B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:27 2024-05-08 pm EDT			After market 06:07:21 pm
160.4 ^USD	-1.29%		161.4	+0.62%

May. 08	AbbVie Says Canadian Regulator Expands Qulipta Indication to Cover Chronic Migraine	MT
May. 08	Daiwa Securities Adjusts Price Target on AbbVie to $171 From $190	MT